Most importantly, there is a significantly increased prevalence of TP53 gene aberrations at relapse [34,44,51], which provides clear evidence that disruption of p53 function is an important driver in DLBCL relapse. The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.